Retinal Biologics Market Size

Retinal Biologics Market size was valued at USD 23.4 billion in 2023 and is anticipated grow at a CAGR of 8.2% between 2024 and 2032, driven by increasing prevalence of retinal diseases, particularly age-related macular degeneration (AMD) and diabetic retinopathy. Growing aging populations coupled with higher rates of diabetes contribute to this growth.

Additionally, advancements in treatment options, such as longer-lasting therapies and combination treatments that enhance patient outcomes and convenience increase the adoption of retinal biologics therapies, further enhancing market growth. Moreover, robust R&D efforts focused on expanding indications for existing biologics as a potential breakthrough for genetic retinal disorders, is contributing to the market growth.

Retinal biologics refers to biological therapies or drugs that are specifically used to treat diseases and conditions affecting the retina, such as age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion, among others. Biologics are typically derived from living organisms and are designed to target specific molecules or pathways involved in disease processes. They may include monoclonal antibodies or proteins that can inhibit certain growth factors or other mediators involved in retinal diseases. Examples of retinal biologics include anti-vascular endothelial growth factor (anti-VEGF) agents such as ranibizumab, bevacizumab, and aflibercept, which are used to treat macular degeneration and other retinal conditions.